Germany-based multinational science and technology company Merck has opened a new commercial facility at its existing site in Martillac, France. The 2,700m2 site offers contract testing, development and manufacturing (CTDMO) services that will simplify the commercialisation experience for clients and improve speed to market.
The facility will focus on providing a global supply of commercial drug substances including monoclonal antibodies and other recombinant proteins. It also features state-of-the-art single-use equipment and onsite regulatory, quality and technical experts.
Merck’s Millipore CTDMO services form part of its Life Science Services business unit, which, along with the Process Solutions branch, is one of the company’s ‘big three’ growth drivers. The company aims to achieve revenue of approximately €25bn ($24.6bn) by 2025.
In order to boost sales, the company plans to significantly increase its total investments between 2021 and 2025 compared with the 2016–20 period. Recently Merck announced several investment projects in its Life Science Services business unit, including site expansions across China, France, Germany, Ireland, Switzerland and the US to support growing global demand for life-saving medications.